Vontobel Holding Ltd. Sells 1,348,304 Shares of Boston Scientific Corporation (NYSE:BSX)

Vontobel Holding Ltd. reduced its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 24.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,270,166 shares of the medical equipment provider's stock after selling 1,348,304 shares during the period. Boston Scientific makes up about 1.6% of Vontobel Holding Ltd.'s holdings, making the stock its 18th largest holding. Vontobel Holding Ltd. owned about 0.29% of Boston Scientific worth $430,774,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in BSX. Vanguard Group Inc. lifted its position in shares of Boston Scientific by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider's stock worth $11,869,805,000 after buying an additional 1,600,062 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Boston Scientific by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock valued at $3,230,293,000 after buying an additional 3,344,571 shares during the period. Geode Capital Management LLC increased its holdings in shares of Boston Scientific by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider's stock valued at $2,729,371,000 after purchasing an additional 1,041,329 shares in the last quarter. Capital World Investors increased its stake in Boston Scientific by 28.7% in the 4th quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock valued at $2,492,041,000 after purchasing an additional 6,216,199 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in Boston Scientific by 2.5% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider's stock worth $1,992,994,000 after purchasing an additional 554,388 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,314 shares of Boston Scientific stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the transaction, the executive vice president owned 22,235 shares in the company, valued at $2,269,304.10. The trade was a 43.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president directly owned 36,193 shares of the company's stock, valued at $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 461,970 shares of company stock worth $47,755,193 over the last ninety days. 0.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

BSX has been the topic of several recent analyst reports. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. Royal Bank Of Canada lifted their price objective on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Leerink Partners started coverage on Boston Scientific in a research report on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price for the company. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Citigroup restated a "buy" rating and set a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Twenty-two equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Boston Scientific currently has an average rating of "Buy" and a consensus price target of $116.09.

Boston Scientific Stock Performance

BSX stock traded up $0.67 during mid-day trading on Friday, reaching $104.30. 2,931,148 shares of the stock traded hands, compared to its average volume of 6,658,145. The firm has a market capitalization of $154.30 billion, a PE ratio of 76.13, a P/E/G ratio of 2.69 and a beta of 0.68. Boston Scientific Corporation has a 52 week low of $71.88 and a 52 week high of $107.53. The business has a 50-day moving average of $103.37 and a two-hundred day moving average of $99.96. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The company's revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.56 earnings per share. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.